Research Article
Loss of CADM1/TSLC1 Expression Is Associated with Poor Clinical Outcome in Patients with Esophageal Squamous Cell Carcinoma
Table 1
Relationship between CADM1/TSLC1 expression and clinicopathological variables of ESCC.
| Variable | CADM1/TSLC1 expression | value | Positive () | Negative () |
| Age (years) | | | 0.145 | <60 | 128 (54.2%) | 37 (64.9%) | | ≥60 | 108 (45.8%) | 20 (35.1%) | | Sex | | | 0.032 | Male | 171 (72.5%) | 33 (57.9%) | | Female | 65 (27.5%) | 24 (42.1%) | | Location | | | 0.674 | Upper thoracic | 25 (10.6%) | 4 (7.0%) | | Middle thoracic | 179 (75.8%) | 46 (80.7%) | | Lower thoracic | 32 (13.6%) | 7 (12.3%) | | Histological grade | | | 0.000 | I | 77 (32.6%) | 12 (21.1%) | | II | 145 (61.4%) | 18 (31.6%) | | III | 14 (6.0%) | 27 (47.3%) | | Depth of invasion | | | 0.791 | T1-2 | 46 (19.5%) | 12 (21.1%) | | T3-4 | 190 (80.5%) | 45 (78.9%) | | Tumor size (cm) | | | 0.410 | ≤5 | 165 (70.0%) | 43 (75.4%) | | >5 | 71 (30.0%) | 14 (24.6%) | | Lymph node metastasis | | | 0.997 | Positive | 116 (49.2%) | 28 (49.1%) | | Negative | 120 (50.8%) | 29 (50.9%) | | TNM stage | | | 0.905 | I-II | 118 (50.0%) | 28 (49.1%) | | III | 118 (50.0%) | 29 (50.9%) | |
|
|